Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab retreatment study in primary Sjögren syndrome after prior placebo-controlled trial
NL-OMON32498Phase 2Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in primary Sjögren's syndrome (2 cohorts), sponsored by University Medical Center Groningen. Primary endpoint: Stimulated salivary gland function. Planned start Sep 2008; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON32498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32498.